Navigation Links
Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
Date:7/10/2008

s relating to cord blood services, and from the sale of sub-license agreements by licensees.

As of May 31, 2008, the Company had approximately $4.2 million in available cash, cash equivalents, marketable securities and other investments. The Company had no long-term debt at the end of the quarter.

"We continue to be encouraged by Cryo-Cell's improved performance in the second quarter of 2008. In accordance with our long-term strategic plan, we believe that the Company is showing significant progress with the launch of our new product, C'elle, combined with the realization of significant operating efficiencies that have resulted in year over year expense reductions of 21% in the first half of fiscal 2008," stated Mercedes Walton, Chairman and Chief Executive Officer. "In 2006, following nine consecutive quarters of profitability spanning the first quarter of 2004 through the second quarter of 2006, Cryo-Cell's Board of Directors made the deliberate decision to forsake continued near-term profitability in order to invest in the long-term growth of our business. During the first half of fiscal 2008, Cryo-Cell has demonstrated continuing progress towards profitability and we anticipate future progress in 2008 and beyond based on our solid platform as an industry leader of innovative stem cell solutions."

"Notwithstanding formidable challenges facing our business associated with the overall impact of the domestic economy on discretionary consumer and family spending, intensified industry competition and the cost of new product development, Cryo-Cell has now introduced a highly differentiated new service in the U.S. and is making significant progress toward introducing the new service in the global market place based on our expansive intellectual property portfolio. In parallel, the Company has also achieved impressive reductions in marketing, general and administrative expenses." Walton continued, "Our recent agreement with LifeCell International Pri
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
4. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
5. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
6. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
7. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
8. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
9. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
10. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
11. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... Virginia (PRWEB) October 20, 2014 ... NDA Partners LLC, announced today that Ellen Teplitzky, ... legal support for the pharmaceutical industry, has joined ... manager of its legal services practice. NDA ... and expert witness and testimony, to top law ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Life Length®, the world,s leading telomere testing ... Inc ("ADL") of Boca Raton, Florida to offer its test ... tissue samples to be forwarded to Life Length,s lab in ... Length said, "We are delighted to partner with ADL. This ...
... Inc. today announced that two studies of SL-401, a ... malignancies, have also demonstrated preclinical activity against a variety ... at the upcoming 53rd Annual Meeting of the American ... Diego, CA from December 10-13, 2011. ...
... RATON, Fla., Dec. 7, 2011 /PRNewswire-iReach/ -- ... Herb Pharma, Switzerland: the best and most powerful weapons ... Although aging is a natural process, no-one ... neck and decolletage, which are on display most of ...
Cached Biology Technology:Life Length Telomere Test Available Nationwide 2Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH) 2Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH) 3Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH) 4Fytofontana Cosmeceuticals: The Swiss Secret For Incredibly Young And Beautiful Skin 2
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... is a dancer,s instrument, but is it attuned to the ... suggests that professional ballet and modern dancers are not as ... regularly practice meditation. UC Berkeley researchers tracked how closely ... changes such as breathing and heart rates. They found ...
... A team involving University of Tennessee, Knoxville, researchers ... algal bloom (HAB) species, cracking the genome of the ... Brown tides decimated the scallop industries of New ... and continue to plague the waters off North America ...
... is central to cell function, as it converts the information ... which then program protein synthesis. The enzyme RNA polymerase II ... prone to transcriptional arrest. The biochemist Professor Patrick Cramer, Director ... have now shown for the first time and captured ...
Cached Biology News:Meditation beats dance for harmonizing body and mind 2UT researchers crack code to harmful brown tides 2Stop and go 2
... MiniPrep series of robotic workstations is designed ... MiniPrep is the ideal automation platform for ... routine laboratory procedures, improving throughput, process consistency ... for MiniPrep software allows you to control ...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
Biology Products: